AI-based medical and healthcare devices and systems have unique characteristics including 1) plasticity causing changes in system performance through learning, and need of creating new concepts about the timing of learning and assignment of responsibilities for risk management; 2) unpredictability of system behavior in response to unknown inputs due to the black box characteristics precluding deductive output prediction; and 3) need of assuring the characteristics of datasets to be used for learning and evaluation. The Subcommittee on Arti cial Intelligence and its Applications in Medical Field of the Science Board, the Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan, examined new elements speci c to AI not included in conventional technologies, thereby clarifying the characteristics and risks of AI-based technologies. This paper summarizes the characteristics and clinical positioning of AI medical systems and their applications from the viewpoint of regulatory science, and presents the issues related to the characteristics and reliability of data sets in machine learning.
Introduction
The applications of arti cial intelligence (AI)-based new technologies have been actively investigated in various elds including medical care. However, there have been certain concerns over the applications of the AI to medical care. The use of AI might pose different types of potential risks yet to be discussed in the sense of regulatory science. Such discussion would cover the proper use of AI-based technologies, and would also involve the users, not only the manufacturers.
The Pharmaceuticals and Medical Devices Agency (PMDA: Japanese regulatory agency) organized a Subcommittee on Arti cial Intelligence and its Applications in Medical Field under the Science Board to examine and report the impact of AI medical care applications. It is intended to clarify the characteristics and potential risks of AI-based technologies, then to propose the basis of clinical use, and to contribute to the future review and consultation services by PMDA.
This paper is a summary of the discussion and the report of the Subcommittee submitted to PMDA. Its scope is not limited to medical devices and software under the current regulation in Japan.
AI in Medical and Healthcare Applications
The research and development of AI are now in its third boom since its start at the famous Dartmouth Conference in 1956. The current attention is on machine learning, particularly deep learning, and large-scale knowledge utilization represented by IBM Watson. The capability of computer to collect and use massive data has contributed signi cantly to the third boom. The widespread use of the Internet enables on-line collection of massive knowledge and data, and massive storage devices also become affordable [1] i . The technical advancement stimulated creation of new algorithms assuming and requiring such massive storage and huge computation capabilities. Such AI-based systems are expected to change the relationship between human beings and computers. In the past, humans understood and controlled the behaviors of the computers. Now, the computers exceed humans in memory and computation capabilities as well as the performance of certain AI-based systems to solve speci c tasks.
The applications of AI particularly in machine learning has an enormous potential in medical care. For instance, AI-based systems using large numbers of reported diagnostic images already surpassed the performance of human radiologists. However, the concern of the human-computer relationship would also impact medical care applications. Another fact, indeed our core concern, is that certain portion of the AI-based medical systems are considered to be medical devices under the stringent regulation in many nations/regions. The authors consider that it is crucially important to establish the key points to perform evaluation and regulatory review of AI-based medical systems -the evaluation and review should be grounded on the understanding of the characteristics of AI and its potential risks.
AI Medical Systems
This section provides a view from regulatory science on AI-based medical devices/systems and other AI-based healthcare devices/systems (hereinafter referred to as the AI medical systems), by looking at a couple of speci c applications in diagnostic and treatment assistance, namely AI-based computer-aided diagnosis (CAD) and surgical robots with a degree of autonomy.
Characteristics of AI medical systems
The AI medical systems are different from conventional medical devices and systems in the following three aspects: 1) plasticity, 2) predictability, and 3) degree of autonomy. This subsection discusses the impacts of these three aspects.
Plasticity
The AI medical systems are capable of self-changing their performance through learning (i.e. plasticity). Although medical devices and systems with adaptively changing behavior already existed in the past, such as background noise level setting of the electrocardiac monitoring of automatic external de brillators, the AI medical systems can have qualitatively different plasticity from conventional devices and systems. Table 1 shows the classi cation of AI medical systems by the timing of learning and the timing of performance change. When the performance of the system changes dynamically by learning after use is started, the regulatory concern is the conformity to the marketing approval. If the approval includes the performance criteria (in most of cases it does), a departure from the approval criteria due to performance change may necessitate par- Performance dynamically changes by learning. Performance may be worsened by improper learning. Control of learning and the dataset by the manufacturer can be tricky.
i Le et al. [1] , processed data from 10 million images using a group of computers of 16,000 cores in 3 days. IBM Watson processes about 70 GB data (corresponding to 2 hundred million pages of a book) using about 3,000 processors.
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( 119) tial change of registration. Another concern is that maintenance of risk management by the manufacturer will be tricky. It should be noted that the performance change may not always be positive, i.e. it may be worsened by improper learning. Maintaining risk management is a part of regulatory requirement in most nations and regions in the world. The manufacturer controls the learning prior to the start of shipment or service of the AI medical system. The manufacturer also controls the dataset used for learning in the same manner of that for conventional medical device. However, learning after shipment/starting service may not be done by the manufacturer -the users, i.e. medical practitioners, may also apply learning using their data. It is an issue about who shares the responsibility of risk management.
Predictability
Another factor in uencing the effect of AI is the unpredictability of the AI output due to the black box nature of the machine learning algorithms typically seen in deep learning. Its output can be dif cult to predict or interpret in a deductive manner. This factor has an impact on the risk management conducted by the manufacturer. The outputs from AI medical systems are classi ed into three patterns in terms of the predictability of the output as illustrated in Fig. 1 . (a) Output is selected from a given, nite number of solutions. For example, an AI medical system outputs feasible diagnosis from among predetermined options. (b) Output is selected from a given, nite range of solu tions. For example, an AI medical system for computer assisted diagnosis outputs possible lesion site and probability in a range of 0 to 1. (c) Output is not predetermined. For example, a new category of disease is created by an AI medical system.
Degree of autonomy
Further advance the AI medical systems may modify the relationship between doctors and patients. Autonomy, which is another characteristic of the AI medical systems, has been discussed from various viewpoints. The case of automated car driving has attracted public attention [2] . Similar discussion is found in the editorial by Yang et.al. [3] , that advancement of AI-based technologies and resultant higher degree of autonomy will change the relationship between the doctors and the patients. Although the future AI may acquire the ability to provide diagnosis or even treatment plan without human intervention, this paper does not discuss this
Types of AI medical systems 3.2.1 AI CAD
AI CAD is a typical example of AI-based diagnostic systems. The main input into the AI CAD are the diagnostic images. The AI CAD can be classi ed into 5 diagnostic assistance levels (DL1 to DL5) as follows. D L1: AI CAD calculates and presents the feature value related to a disease (e.g. indication of a lesion, diameter or volume of a tumor) to doctors to assist the diagnostic decision. It is known as computer-aided detection (CADe). D L2: AI CAD calculates and presents a diagnostic suggestion (e.g. malignancy, staging) to doctors to assist the diagnostic decision or to prevent oversights. D L3: AI CAD processes images and other clinical information (multimodal information) and presents a comprehensive diagnosis to doctors to assist the diagnostic decision. D L4: AI CAD processes multimodal information and provides an automated diagnosis to doctors. The doctors must review and approve the diagnosis. D L5: AI CAD processes multimodal information and provides a fully automated diagnosis without doctors intervention and review. It should be noted that DL1 and DL2 are found in the conventional CAD typically to assist radiologists to prevent oversight, while DL3 and higher aim at comprehensive or automated diagnosis that may play the role traditionally considered as that of doctors.
AI surgical robot
Surgical robot with AI-based treatment assistance (AI surgical robot) can be an example of AI-based treatment systems. Yang, et al. proposed the levels of autonomy of medical robots for consideration of regulatory issues [3] .
AI-based treatment systems can be characterized by the direct effect of outputs to the patients: AI can be involved in treatment in a more direct manner than in the case of diagnosis. The predictability of outputs and the time margin to mitigate erroneous behavior by the system also need to be considered. IEC TR 60601-4-1 pro- Fig. 1 Classi cation of AI medical systems in terms of predictability of the output.
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Characteristics of the dataset
The following subsection describes the preferred data characteristics used for learning or testing ii (evaluation) of AI medical systems, mainly regarding the scienti c soundness of the data. We assume that other characteristics including ethical and reliability issues such as personal data protection are prerequisites.
Characteristics of the dataset for AI CAD
The conventional CAD also used clinical image and sometimes synthesized data for the testing. Such test data were the images of the intended region, diseases and modalities. The manufacturers must clarify the characteristics of these data, such as the sampling method, to demonstrate the freedom from bias.
In case of AI CAD, the following factors can be applicable to the dataset for learning and testing. These do not exist in the case of conventional CAD. 1) It is generally expected that an AI-based system performs accurately only to the extent that suf cient learning data have been given. It will not perform accurately if the learning data are insuf cient. Therefore, the AI CAD should be developed using images with a suf cient range of diseases corresponding to the extent of the product s intended use. 2) Transfer learning may use images other than the images of the intended region, diseases and modalities, including even natural images. 3) Algorithms such as unsupervised learning, semi-supervised learning, and learning with weak labels can technically use images lacking full information, for example the truth labels. A huge amount of such image data is available from the Internet. Use of such data also needs to address the issue of reliability. 4) To increase the learning data, synthetic data may be used. Linear transformation (including rotation, scaling, and translation) and non-linear transformation applied to the original learning data, or the generation mode (such as an autoencoder) may be used to synthesize data. The testing data shall be distinguished from the learning data. However, it is not easy to completely prevent contamination between these data. It is also effective for the AI medical systems to be equipped with an appropriate management system and a function to roll back the system to the state before contamination or to the initial state.
Characteristics of dataset for AI-based treatment system
In addition to the factors stated in the previous section, the followings factors may be applicable to the dataset for learning and testing of AI-based treatment systems. 1) There are cases in which it is dif cult to de ne the ground truth and metrics for the test. Although manufacturers may and can de ne these, they need to justify the de nition. 2) Collection of controlled and homogeneous data of diseases, treatments, or doctors is possible in a limited number of cases. Using inhomogeneous data may result in an unwanted bias. Particular attention should be paid especially when treatment strategies or surgical techniques differ among medical institutions.
3) The data of treatment assistance are often associated with the time sequence. Such data are useful and allow accurate learning when they are linked to phases of tasks. 4) The attributes of doctors such as career history and experience should be considered in the analysis. The learning curve should also be considered when the medical device being tested is new and the doctors are considered unfamiliar to it. These factors can be seen in clinical evaluations of conventional medical devices regardless of the use of AIbased technologies.
In addition to patients medical records, data from the decisions and actions of medical practitioners as well as the system logs are valuable sources for learning. However, since such data have not been handled as medical information, the quality assurance of such data, the collection method and tools, the ownership of the data, and the protection of personal information need to be further discussed.
Risk analysis and control
The quality, ef cacy, and safety of AI medical systems within the intended use are equally important as those of conventional medical devices and systems. However, introducing AI-based technology may pose additional hazards not seen in the conventional medical devices and systems.
IEC TR 60601-4-1:2017 states that the degree of autonomy of medical electrical equipment and systems does not correlate with the level of risk. Similarly, it can ii The term validation referred to a process to determine the hyper parameters in a network structure in deep learning, while the same term is used differently in IEC 82304-1:2016. For the purpose of this report the term test is collectively used to refer to validation in IEC82304-1 and the unit and system tests in IEC 62304. Kiyoyuki CHINZEI, be considered that the level of risk by introducing an AIbased technology does not correlate with the level of the AI. For example, an AI medical system may bring a new hazard, it may also reduce the frequency or severity of other more serious harms, and as the result, the overall risk of the system may be evaluated as acceptable. Regulatory bodies look at the overall balance between risks and bene ts of a medical device as a whole, not the piecewise risks of components.
Risk analysis and control of AI CAD
The typical risks associated with AI CAD according to the diagnostic assistance level shown in Section 3.2.1 are summarized below. The actual risks and the levels depend on individual CAD system and its intended performance. If the expected performance is high, the in uence of a risk can be signi cant, and vice versa. D L1: Measurements are simple, and the inaccuracy of the output can be a hazard. Associated risks are expected to be low relative to the other levels. D L2: The output can strongly in uence the decision making of the doctors. Therefore, reasonable accuracy is required. The consequence of incorrect information may in uence the treatment. The associated risks may be raised. D L3: The output is considered comprehensive, and the chance of doctors identify the erroneous output can be low. Therefore, the accuracy should be equally high or even higher than that of doctors. D L4: The accuracy of the output should be higher than that of doctors. One notable hazardous situation is the loss of situation awareness resulting in doctors blindly approving the output. D L5: No human doctor is involved to correct an erroneous output. The consequence directly results in failure of the treatment. It is well known that it is dif cult for humans to predict the behavior of deep learning and other neural network algorithms due to the black box nature mentioned in Section 3.1.2. When an AI CAD does not perform as expected, analyzing it to identify the source of error is not straightforward. Therefore, it is important to clarify the probability of incorrect performance and ensure the user s proper situation awareness.
There is another risk of cyberattack resulting in incorrect and unreliable output. Such attack may include, but not limited to, contamination by malicious data and sabotage resulting in biased data. Attack can be dif cult to detect from the behavior of the system. The topic of risk management against cyberattack will need further discussion regarding the extent of measures that is required against such attack.
Risk analysis for treatment system
The indirect/direct effects and predictability of the outputs are important for analyzing the risks associated with the AI-based treatment systems.
The lag time until the system operator recognizes and intervenes in a hazardous situation is related to the risks of an AI-based treatment system. The AI is expected to avoid the hazardous situations to reduce risks when there is only limited time for the operator to react. In this regard, however, it is well known in other elds such as aeronautical engineering, that leaving safety monitoring to automatic systems can cause another problem of loss of situation awareness by the operators.
Conclusion
The AI medical systems have unique characteristics including 1) plasticity causing changes of system performance through learning and the need of creating new concepts about the timing of learning and assignment of responsibilities for risk management; 2) unpredictability of system behavior due to the black box characteristics precluding deductive output prediction; and 3) the need of assuring the characteristics of datasets for learning and the datasets for evaluation. We have summarized the characteristics and clinical positioning of the AI medical systems, their application types from a viewpoint of regulatory science, and the issues related to the characteristics of datasets in machine learning. Further advance of the assistance level by AI medical systems may also change the relationship between doctors and patients. The learning methods such as transfer learning, unsupervised learning, semi-supervised learning, and learning with weak labels introduce new factors to be considered in regulatory processes. Dataset should be appropriately managed considering the nature of the AI-based technologies and regulatory requirements. If the AI is trained by users of AI medical systems, such as doctors and other medical practitioners, dataset control and risk management would not be as stringent as when done by the manufacturers. This will introduce a new issue on how to share the responsibility of performance assurance after learning by different stakeholders. The ethics viewpoint is not discussed in this paper, although a certain consensus in society will be needed. The users of AI-based technologies in medical applications are asked to be aware of these new issues.
